Your browser doesn't support javascript.
loading
Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design.
Fjellström, Ola; Akkaya, Sibel; Beisel, Hans-Georg; Eriksson, Per-Olof; Erixon, Karl; Gustafsson, David; Jurva, Ulrik; Kang, Daiwu; Karis, David; Knecht, Wolfgang; Nerme, Viveca; Nilsson, Ingemar; Olsson, Thomas; Redzic, Alma; Roth, Robert; Sandmark, Jenny; Tigerström, Anna; Öster, Linda.
Afiliação
  • Fjellström O; Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Akkaya S; Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Beisel HG; Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Eriksson PO; Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden.
  • Erixon K; Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Gustafsson D; Bioscience, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Jurva U; Drug Metabolism and Pharmacokinetics, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Kang D; Bioscience, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Karis D; Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Knecht W; Bioscience, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Nerme V; Bioscience, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Nilsson I; Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Olsson T; Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Redzic A; Medicinal Chemistry, Cardiovascular & Metabolic Diseases Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden.
  • Roth R; Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden.
  • Sandmark J; Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden.
  • Tigerström A; Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden.
  • Öster L; Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden.
PLoS One ; 10(1): e0113705, 2015.
Article em En | MEDLINE | ID: mdl-25629509
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Fator XIa / Inibidores de Serina Proteinase / Relação Quantitativa Estrutura-Atividade / Avaliação Pré-Clínica de Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Fator XIa / Inibidores de Serina Proteinase / Relação Quantitativa Estrutura-Atividade / Avaliação Pré-Clínica de Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article